Weight-Loss Drugs Are a 'Regressive Tax on Being Thin'
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Baringa Partners analysis found GLP-1 users need roughly £97,500 in discretionary income for grocery savings to offset the £1,200 annual drug cost, while those with £39,000 left over save just £481 on food.
- Paddy Winters, partner at Baringa, called GLP-1 medications a "regressive tax on being thin," noting users also spend more on vitamin supplements and personal care products to manage side effects.
- Winters flagged a "start, stop, regain and return" pattern, warning some users turn to debt to fund repeat prescriptions after weight returns once they stop the drug.
- PwC research estimates 5% of British adults (nearly 3 million) currently use weight-loss medication, projected to rise to 13% by the end of next year; 60% of users are women.
- PwC data shows the user base skews wealthy: 20% come from households earning above £100,000, while only 6% earn under £20,000.
- Dr Leyla Hannbeck, executive chair of the Independent Pharmacies Association, said NHS access is limited to a small eligible cohort, forcing most patients to pay privately.
- The King's Fund reports 14.3 million adults in England live with obesity and warned the government must not let weight-loss drugs "widen health inequalities" through affordability gaps.
- Mounjaro's price more than doubled in summer 2025, though Hannbeck said the market is becoming more competitive with the recent launch of the Wegovy pill and a growing pipeline of oral GLP-1 formulations.
Why it matters: With roughly 3 million Britons already on weight-loss medication and that figure projected to hit 13% of adults by next year, the regressive cost structure means obesity treatment is effectively a luxury good. Lower-income users face a costly start-stop-regain cycle that risks deepening the very health inequalities the drugs are meant to address.
Ask SkimNews
